Bladder Cancer. Malignant neoplasm of bladder, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients with non-muscle invasive bladder cancer subgroup of intermediate-risk who undergo 6 intravesical injections of 1 g of vial Gemcitabine for 2 hours at one-w
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All the patients with bladder cancer who are not candidates for chemotherapy or bladder removal surgery. Patients with no history of TURT surgery. Patients have no history of intravesical injections. Patients respond to the initial pathology under the moderate risk group with no muscle involvement.
Exclusion criteria
Exclusion criteria: Patients with ruptured bladder during TURT surgery. Patients with immunodeficiency. Patients who are pregnant. Patients who are unable to perform TURT due to urethral stricture or urethral obstruction. Patients with a history of intravesical injections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of bladder cancer. Timepoint: First, a cystoscopy will be performed one month after the last injection into the bladder. Then, in the first year, it will be evaluated by cystoscopy every 3 months, and then every 6 months by cystoscopy. Method of measurement: Direct observation inside the bladder through cystoscopy. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Ali Hojjati
Shahid Beheshti University of Medical Sciences
Outcome results
None listed